Abstract:Background: Primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH) are common causes of hypercalcaemia. Patients are mostly asymptomatic in the case of FHH and often so in the case of PHPT. In addition, biochemical parameters show considerable overlap, making differential diagnosis difficult. Genetic screening for inactivating variants in the calcium-sensing receptor (CASR) gene that are causative of FHH assists with the diagnosis since such variants are not generally associated with PHPT. However, novel CASR variants must undergo functional assessment before they can be definitively assigned a causative role in FHH. Case Presentations. We describe a 73-year-old female (patient A) who presented with mild parathyroid hormone (PTH)-dependent hypercalcaemia and a history of osteoporosis. Family history revealed that her sister (patient B) had presented a decade earlier with symptoms of PHPT including a history of mild hypercalcaemia and multiple renal calculi, prompting parathyroid surgery. However, a subtotal parathyroidectomy did not resolve her hypercalcaemia long term. On this basis, genetic screening was performed on patient A. This identified a heterozygous variant in the CASR, NM_000388.4:c.T101C: p.Leu34Pro (L34P). Functional analysis showed that the L34P variant was unable to produce mature, dimerized receptor and did not respond to Ca++ ions. Adopting American College of Medical Genetics-based guidelines, the variant was classified as 'Pathogenic (II)'. Patient B was subsequently found to carry the L34P variant heterozygously, confirming a diagnosis of FHH, not PHPT. Conclusion: This study shows the importance of examining patient's family history in providing clues to the diagnosis in isolated cases of hypercalcaemia. In this case, history of a sister's unsuccessful parathyroidectomy prompted genetic screening in a patient who might otherwise have undergone inappropriate parathyroid surgery. Screening detected an inactivating CASR variant, firming up a diagnosis of FHH. These studies reaffirm the requirement for functionally assessing novel CASR variants prior to assigning causality to FHH.

Novel Homozygous Inactivating Mutation of the Calcium-Sensing Receptor Gene in Neonatal Severe Hyperparathyroidism Responding to Cinacalcet Therapy

Novel homozygous inactivating mutation of the calcium-sensing receptor gene in neonatal severe hyperparathyroidism responding to cinacalcet therapy: A case report and literature review.

Homocystinuria In A Family With Novel Cystathionine Beta Synthase Gene Mutations

Clinical characteristics and genetic analysis of two children with Neonatal severe hyperparathyroidism

One Pedigree Analysis of a Familial Hypocalciuric Hypercalcemia Caused by a New Heterozygous Mutation in Calcium-Sensing Receptor Gene

Identification of a Novel Mutation in Pseudohypoparathyroidism Type Ia in a Chinese Family

Familial hypocalciuric hypercalcemia in an infant: diagnosis and management quandaries

Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience

Safety and Efficacy of Cinacalcet in Children Aged Under 3 Years on Maintenance Dialysis

Identification and Functional Characterization of a Calcium-Sensing Receptor Mutation in an Infant with Familial Hypocalciuric Hypercalcemia

Case Presentation: Functional Assessment of a CASR Variant Identified in a Patient with Hypercalcaemia Confirms Familial Hypocalciuric Hypercalcaemia in the Patient and a Sister Previously Misdiagnosed with Primary Hyperparathyroidism

Three Siblings With Familial Isolated Hypoparathyroidism: A Diagnostic Journey From CASR to Novel GCM2 Variant

Neonatal Severe Primary Hyperparathyroidism—Presentation, Management, and Follow-up of Seven Cases

[Familial Hypocalciuric Hypercalcemia Type 1 Likely Secondary to a New Inactivating Mutation of CASR]

Rare Cause of Infantile Hypercalcemia: A Novel Mutation in the SLC34A1 Gene

Autosomal dominant hypocalcemia with a novel <i>CASR</i> mutation: a case study and literature review

Antenatal presentation and early postnatal treatment of infantile hypercalcemia type 2

A Case of Delayed Diagnosis of Idiopathic Infantile Hypercalcemia Due to CYP24A1 Mutation: A 10-Year Journey

The R900S Mutation in CACNA1S Associated with Hypokalemic Periodic Paralysis

Case report: Familial hypoparathyroidism with elevated parathyroid hormone due to an inactivating PTH mutation

Clinical heterogeneity and therapeutic options for idiopathic infantile hypercalcemia caused by CYP24A1 pathogenic variant